2 Pekeris Street
86 articles with CollPlant
CollPlant, a regenerative medicine company, announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments.
CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committee
The Industry Relations Committee represents all aspects of Biofabrication including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization
CollPlant, a regenerative medicine company, announced financial results for the second quarter ended June 30, 2019 and provided an update on the Company's business developments.
Includes $3.5M from group of U.S. accredited investors with deep expertise in 3D printing
CollPlant Biotechnologies to Present at the 21st Annual Rodman & Renshaw Global Investment Conference
CollPlant announced that Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Tuesday, September 10th, 2019 at 1:45 pm EDT.
Investors include CollPlant's largest shareholder and U.S. tech investors
CollPlant, a regenerative medicine company, announced that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes.
Clinical Results From CollPlant's Advanced Wound Care Product VergenixFG to Be Presented at European Wound Management Association Conference
CollPlant, a regenerative medicine company, announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound Management Association.
CollPlant announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company's business developments.
CollPlant Presents Its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece
CollPlant announced that Dr. Nadav Orr, presented the utilization of CollPlant's recombinant human collagen (rhCollagen) in the field of 3D Bioprinting tissues and organs at the Annual Meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Union Chapter in Rhodes, Greece on Monday, May 27, 2019.
CollPlant, a regenerative medicine company, has launched a new HQ and R&D center in Israel.
CollPlant, a regenerative medicine company, announced the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 10:00 am ET in the Lotus East room of the Mandarin Oriental Hotel in New York City.
CollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics
Distribution in Europe, Middle East, India and Africa for the treatment of tendinopathy
Study Published in Wounds Journal Shows Remarkable Wound Closure Performance With CollPlant's VergenixFG in the Treatment of Chronic Wounds With a 94% Median Wound Area Reduction Within 4-weeks
CollPlant, a regenerative medicine company, announced results from a clinical study conducted with its VergenixFG wound care product.
CollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body
Facility produces proprietary rhCollagen used for BioInks in 3D bioprinting of organs and for dermal fillers
CollPlant, a regenerative medicine company, announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately.
CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
Collaboration Combines CollPlant’s Proprietary rhCollagen-based BioInk Technology and United Therapeutics’ Regenerative Medicine and Organ Manufacturing Capabilities
CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringing the Nasdaq Stock Market Opening Bell on Thursday, November 8, 2018.
Last trading day on the Tel Aviv Stock Exchange (TASE) on October 29, 2018
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant
Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities